Enlivex Therapeutics Ltd (ENLV)
NASDAQ:ENLV
Want to see ENLV full AI Analyst Report?
ENLV Stock Chart & Stats
$0.86
-$0.07(-5.60%)
At close: 4:00 PM EST
$0.86
-$0.07(-5.60%)
Day’s Range― - ―
52-Week Range$0.66 - $2.10
Previous CloseN/A
Volume59.48K
Average Volume (3M)182.02K
Market Cap
$173.31M
Enterprise Value$18.33M
Total Cash (Recent Filing)$5.87M
Total Debt (Recent Filing)$641.00K
Price to Earnings (P/E)<0.1
Beta0.63
Next Earnings
Apr 23, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)27.02
Shares Outstanding241,048,720
10 Day Avg. Volume216,695
30 Day Avg. Volume182,016
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.02
Price to Sales (P/S)0.00
P/FCF Ratio-3.07
Enterprise Value/Market Cap0.11
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-55.20
Enterprise Value/Ebitda-1.28
Forecast
1Y Price Target
$20.00Price Target Upside2225.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.34
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low leverage reduces financial risk and gives management flexibility to fund R&D and clinical programs without a heavy interest burden. Over a 2–6 month horizon low debt supports runway and optionality for strategic moves even if operating cash burn continues.
Material Treasury AssetsA large RAIN token treasury provides a substantial alternative asset base and liquidity optionality that materially bolstered equity in 2025. This unconventional treasury can fund clinical programs, buybacks or strategic actions, enhancing balance-sheet optionality over the medium term.
Advancing Clinical ProgramFDA IND clearance, Danish approval and first U.S. dosing mark durable clinical progress for Allocetra in knee osteoarthritis. A statistically powered, multicenter randomized Phase 2b strengthens prospects for late‑stage development and eventual commercialization in a large, aging market.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flows indicate persistent cash burn and reliance on external financing. Even with smaller 2025 outflows, absence of operating revenue means the company will need ongoing capital, which can dilute shareholders and constrain strategic choices.
Earnings Quality RiskThe large 2025 profit arose from mark‑to‑market treasury gains rather than operating progress, reducing predictability of earnings. Reliance on volatile asset revaluations complicates assessment of core biotech performance and increases earnings volatility over months.
NASDAQ Compliance RiskA minimum‑bid deficiency notice creates structural compliance and delisting risk. Potential delisting or remedial actions could impair liquidity, deter institutional investors, and raise capital costs, undermining the company's ability to reliably fund clinical development.
Enlivex News
ENLV FAQ
What was Enlivex Therapeutics Ltd’s price range in the past 12 months?
Enlivex Therapeutics Ltd lowest stock price was $0.66 and its highest was $2.10 in the past 12 months.
What is Enlivex Therapeutics Ltd’s market cap?
Enlivex Therapeutics Ltd’s market cap is $173.31M.
When is Enlivex Therapeutics Ltd’s upcoming earnings report date?
Enlivex Therapeutics Ltd’s upcoming earnings report date is Apr 23, 2027 which is in 314 days.
How were Enlivex Therapeutics Ltd’s earnings last quarter?
Enlivex Therapeutics Ltd released its earnings results on May 22, 2026. The company reported -$0.02 earnings per share for the quarter, the consensus estimate of -$0.02 by $0.
Is Enlivex Therapeutics Ltd overvalued?
According to Wall Street analysts Enlivex Therapeutics Ltd’s price is currently Undervalued.
Does Enlivex Therapeutics Ltd pay dividends?
Enlivex Therapeutics Ltd does not currently pay dividends.
What is Enlivex Therapeutics Ltd’s EPS estimate?
Enlivex Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Enlivex Therapeutics Ltd have?
Enlivex Therapeutics Ltd has 241,048,720 shares outstanding.
What happened to Enlivex Therapeutics Ltd’s price movement after its last earnings report?
Enlivex Therapeutics Ltd reported an EPS of -$0.02 in its last earnings report, expectations of -$0.02. Following the earnings report the stock price went down -0.417%.
Which hedge fund is a major shareholder of Enlivex Therapeutics Ltd?
Currently, no hedge funds are holding shares in ENLV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Enlivex Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.00 (2225.58% Upside)
$20.00 (2225.58% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.2%
Last 30 Days ▲ 8.1%
Last 30 Days ▲ 8.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.96%
12-Months-Change
Fundamentals
Return on Equity
248.08%
Trailing 12-Months
Asset Growth
8304.66%
Trailing 12-Months
Company Description
Enlivex Therapeutics Ltd
Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.
ENLV Earnings Call
Q4 2026
0:00 / 0:00
ENLV Stock 12 Month Forecast
Average Price Target
$20.00
▲(2225.58% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.01% Mutual Funds
0.98% Other Institutional Investors
97.54% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---